GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Sarepta Therapeutics Inc (SRPT) [hlAlert]

Rating:
Mkt Perform
SRPT
up 12.89 %

Sarepta Therapeutics Inc (SRPT) downgraded to Mkt Perform by Leerink Swann

Posted on: Tuesday,  Apr 16, 2013  8:25 AM ET by Leerink Swann

Leerink Swann rated Mkt Perform Sarepta Therapeutics Inc (NASDAQ: SRPT) on 04/16/2013. Previously Leerink Swann rated Outperform Sarepta Therapeutics Inc (NASDAQ:
SRPT) on 03/05/2013., when the stock price was $30.41. Since then, Sarepta Therapeutics Inc has gained 12.89% as of 04/16/2013's recent price of $34.33.
If you would have followed the previous Leerink Swann 's recommendation on SRPT, you would have gained 12.89% of your investment in 42 days.

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI's NEUGENE-based ESPRIT technology will initially be applied to potential treatments for Duchenne muscular dystrophy.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/16/2013 8:25 AM Hold
None
34.33
as of 12/13/2013
1 Week   
1 Month   
3 Months   
1 YTD up  12.89 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/5/2013 8:25 AM Buy
None
30.41

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy